$COR

DURCAN DERMOT MARK purchased $1.1M of COR

DURCAN DERMOT MARK purchased 4,000 shares of Cencora, Inc. (COR) at $266.26 ($1.07M total) on 2026-05-28.

Original reporting
SEC EDGAR · DURCAN DERMOT MARK
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COR
Bullish
medium confidence
Mentioned
$COR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 4,000 shares at a stated price, which can marginally support sentiment but does not provide new guidance, earnings, or deal information.

02

Market read

Traders may note the insider buy as a small positive sentiment datapoint, but it is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not explain motivation, and insider buying alone rarely changes valuation without accompanying operational catalysts.

Relevance 7/10Novelty 4/10Timing: Filed 2026-05-28, after-hours/close timing for the same trading day.

Background

The article is an SEC Form 4 insider transaction disclosure for Cencora, Inc. (COR).

Company-level read

Ticker impact

$CORBullishMedium confidence
Context

Cencora Form 4 shows director Durcan Dermot Mark bought 4,000 shares at $266.26 on 2026-05-28, totaling $1.07M.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by broader disclosures.

Evidence & confidence

The filing is a primary-source insider transaction with clear size and price, but it does not include new company performance, strategy, or regulatory developments.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine, tax-related, or driven by personal liquidity needs, so they may not reflect a new fundamental outlook.

Key entities

  • Cencora, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • DURCAN DERMOT MARK

    Director who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORHighAI 8/10

Is Cencora Stock Underperforming the Dow?

Cencora (COR), a $61.6B pharmaceutical distributor, is down 14% from its 52-week high but up 18.5% over 3 months, outperforming the Dow. Its Q3 revenue missed estimates, but adjusted EPS beat forecasts. Analysts rate it a 'Strong Buy' with a $366.50 target, implying 12.9% upside. Peer Cardinal Health (CAH) gained 60% over the past year.

$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

$CORHighAI 8/10

Why Cencora (COR) Is Getting Attention Today

Cencora (COR) reported Q3 2026 adjusted EPS of $4.48, beating estimates, and raised full-year guidance. Shares fell 1.86% to $330.95 but gained 20.75% over 90 days. The company's long-term returns are strong, with a 1-year return of 14.01% and a 5-year return of 183.23%. Analysts suggest fair value at $372.58, citing digital investments and healthcare trends.

$MCKMedAI 8/10

and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

McKesson (MCK) and Cencora (COR) are positioned to benefit from certain drug price inflation due to contractual provisions. McKesson reported $403.4B revenue and $39.11 EPS for fiscal 2026, with Q1 2027 revenue at $105.4B and EPS at $9.93. Cencora generated $321.3B revenue in fiscal 2025, with Q2 revenue at $78.4B and EPS at $4.75. Both companies have raised EPS forecasts.

$MCKHighAI 9/10

With Price-Increase Clauses, These Two Drug Distributors Can Withstand ‘Trumpflation’

McKesson (MCK) and Cencora (COR) benefit from drug price increases due to inflation-based compensation clauses. McKesson reported $403.4B revenue in 2026, up 12%, and raised EPS guidance. Cencora posted $321.3B revenue in 2025, up 3.8%, and increased EPS guidance. Both companies' contracts allow gains from manufacturer price hikes, but risks include regulation and cost pressures.

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.